Current Rating and Its Significance
MarketsMOJO’s current rating of Sell for Alembic Pharmaceuticals Ltd. indicates a cautious stance towards the stock. This rating suggests that, based on a comprehensive evaluation of the company’s quality, valuation, financial trends, and technical indicators, the stock is expected to underperform relative to the broader market or its sector peers in the near to medium term. Investors should consider this rating as a signal to reassess their exposure to the stock and weigh potential risks carefully.
Rating Update Context
The rating was revised to Sell on 20 July 2026, reflecting a decline in the company’s overall Mojo Score from 51 to 45. While this change marks a shift from a previous Hold rating, it is important to understand that the current analysis is based on data as of 01 August 2026, ensuring that investors have the latest insights into Alembic Pharmaceuticals’ performance and outlook.
Here’s How Alembic Pharmaceuticals Looks Today
As of 01 August 2026, Alembic Pharmaceuticals is classified as a smallcap company within the Pharmaceuticals & Biotechnology sector. The stock has experienced a modest decline recently, with a day change of -0.95% and a one-month return of -3.99%. Over the past year, the stock has underperformed significantly, delivering a negative return of -18.67%, while the broader BSE500 index has generated a positive return of 1.95% during the same period. This underperformance highlights challenges the company faces in maintaining investor confidence and market momentum.
Quality Assessment
The company’s quality grade is currently rated as average. This reflects a mixed picture regarding operational efficiency and profitability. Notably, Alembic Pharmaceuticals has exhibited poor long-term growth, with operating profit declining at an annualised rate of -9.97% over the last five years. Such a trend raises concerns about the company’s ability to sustain earnings growth and compete effectively in a highly competitive pharmaceutical sector.
Valuation Perspective
From a valuation standpoint, Alembic Pharmaceuticals is considered very attractive. This suggests that the stock is trading at a price level that may offer value relative to its earnings, assets, or cash flow. For value-oriented investors, this could represent an opportunity to acquire shares at a discount. However, valuation alone does not guarantee positive returns, especially if underlying business fundamentals remain weak.
Financial Trend Analysis
The financial trend grade is assessed as flat, indicating stagnation in key financial metrics. The latest quarterly results for March 2026 reveal a significant decline in profitability, with Profit Before Tax (PBT) excluding other income falling by 33.68% to ₹117.88 crores. Operating profit to interest coverage ratio has dropped to a low of 10.10 times, and PBDIT for the quarter stands at ₹227.92 crores, the lowest recorded in recent periods. These figures point to pressure on earnings and operational efficiency, which may constrain future growth prospects.
Technical Outlook
Technically, the stock is graded as mildly bearish. This reflects recent price trends and momentum indicators that suggest a cautious or negative near-term outlook. The stock’s price has declined by 0.25% over the past week and 3.99% over the last month, signalling subdued investor sentiment. Such technical signals often influence short-term trading decisions and can impact liquidity and volatility.
Implications for Investors
For investors, the Sell rating combined with the current fundamental and technical assessments suggests prudence. While the stock’s valuation appears attractive, the ongoing challenges in profitability, flat financial trends, and bearish technical signals imply that risks remain elevated. Investors should carefully consider their investment horizon, risk tolerance, and portfolio diversification before increasing exposure to Alembic Pharmaceuticals.
Sector and Market Context
Within the Pharmaceuticals & Biotechnology sector, Alembic Pharmaceuticals’ performance contrasts with some peers that have demonstrated stronger growth and more favourable technical patterns. The company’s smallcap status also means it may be more susceptible to market volatility and liquidity constraints compared to larger, more established players. Monitoring sector trends and regulatory developments remains essential for contextualising the stock’s outlook.
Just made the cut! This Mid Cap from the Heavy Electrical Equipment sector entered our elite Top 1% list recently. Discover it before the crowd catches on!
- - Top-rated across platform
- - Strong price momentum
- - Near-term growth potential
Summary and Outlook
In summary, Alembic Pharmaceuticals Ltd. is currently rated Sell by MarketsMOJO, reflecting a combination of average quality, very attractive valuation, flat financial trends, and mildly bearish technicals. The stock’s recent underperformance relative to the broader market and sector peers underscores the challenges it faces. Investors should approach the stock with caution, recognising that while valuation metrics may offer some appeal, the company’s operational and financial headwinds present significant risks.
Continued monitoring of quarterly results, sector dynamics, and technical developments will be crucial for investors considering Alembic Pharmaceuticals. Those with a higher risk appetite and a long-term perspective may find opportunities if the company can reverse its profit decline and improve operational efficiency. Conversely, more risk-averse investors may prefer to limit exposure until clearer signs of recovery emerge.
About MarketsMOJO Ratings
MarketsMOJO’s rating system integrates multiple dimensions of stock analysis, including quality, valuation, financial trends, and technical indicators, to provide a comprehensive view of a company’s investment potential. The Sell rating signals that, based on current data and trends, the stock is expected to underperform, guiding investors towards more favourable opportunities or caution in portfolio allocation.
Stock Returns Recap
As of 01 August 2026, Alembic Pharmaceuticals has delivered the following returns: a 1-day decline of -0.95%, a 1-week change of -0.25%, a 1-month drop of -3.99%, a 3-month gain of +5.30%, a 6-month increase of +1.65%, a year-to-date loss of -6.33%, and a 1-year negative return of -18.67%. These figures highlight the stock’s recent volatility and longer-term underperformance.
Financial Highlights
The latest quarterly results show a significant contraction in profitability, with PBT excluding other income falling by 33.68% to ₹117.88 crores. Operating profit to interest coverage ratio is at a low 10.10 times, and PBDIT has declined to ₹227.92 crores, marking the lowest quarterly performance in recent history. These metrics illustrate the financial pressures the company is currently facing.
Technical Snapshot
The mildly bearish technical grade reflects subdued price momentum and investor sentiment. The stock’s recent price declines and lack of strong upward momentum suggest caution for traders and investors relying on technical analysis for entry or exit decisions.
Conclusion
Overall, Alembic Pharmaceuticals Ltd.’s Sell rating by MarketsMOJO is grounded in a thorough analysis of its current financial health, valuation, quality, and technical outlook. Investors should carefully evaluate these factors in the context of their investment goals and risk tolerance before making decisions regarding this stock.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
